Engineered tRNA Restores Full-Length Protein in Cystic Fibrosis Nonsense Mutation Models

The team measured read-through efficiency, full-length CFTR protein levels, and channel function using cell lines, organoids, and mouse models carrying common nonsense mutations. Engineered tRNAs carrying a single natural chemical modification showed higher activity and stability than unmodified versions, achieving measurable restoration of protein across multiple genes. Delivery required redesign of lipid nanoparticles to accommodate tRNA cargo size and charge, yielding targeted uptake without the mRNA-focused formulations used in COVID-19 vaccines.

Nonsense mutations account for roughly 11 percent of inherited disorders yet affect thousands of patients with cystic fibrosis, muscular dystrophies, and neurological conditions that lack approved read-through therapies. Existing CFTR modulators address only folding or gating defects and leave nonsense alleles untreated. The study demonstrated additive benefit when tRNA was combined with approved modulators, suggesting a potential combination strategy for compound heterozygous patients.

Prior tRNA suppressor work relied on viral vectors or unmodified molecules with short half-lives and poor delivery. This platform advances the field by integrating synthetic chemistry and nanoparticle engineering, yet remains at the preclinical stage. No human pharmacokinetic, immunogenicity, or off-target read-through data exist.

Next steps require IND-enabling toxicology studies and selection of a lead indication with quantifiable nonsense allele frequency. A first-in-human trial would need to demonstrate safety margins before expansion to ultra-rare mutations sharing the same stop codon.